Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524494 | NSE Symbol : IPCALAB | ISIN : INE571A01038 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
28-Mar-2025	28-Mar-2025	Acquisitions	Outcome of Board Meeting - 28.03.2025
27-Jan-2025	13-Feb-2025	Quarterly Results	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results for Q3 and nine months ended 31st December 2024 Standalone and Consolidated Q3FY25 Results & Press Release (As Per BSE Announcement Dated on: 13/02/2025)
24-Oct-2024	14-Nov-2024	Quarterly Results	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Standalone and Consolidated Financial Results for 2nd quarter and half year ended 30th September 2024 and Declaration of Interim Dividend Board declares Interim Dividend of Rs. 2/- per share of Re. 1/- each (200%) (As per BSE Announcement Dated on 14/11/2024)
23-Sep-2024	30-Sep-2024	Subsidiary Company	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/09/2024 inter alia to consider and approve Integration and consolidation of the generics formulations business in the US market of M/s. Bayshore Pharmaceuticals LLC (wholly owned step-down subsidiary) into Unichem Pharmaceuticals (USA) Inc. (wholly owned subsidiary of Companys subsidiary) Entering into agreements by Bayshore Pharmaceuticals LLC, USA ('Bayshore') (wholly-owned step down subsidiary) with Unichem Laboratories Limited ('Unichem India') (subsidiary company) and Unichem Pharmaceuticals (USA) Inc ('Unichem USA') (wholly owned subsidiary of Unichem India), so as to integrate and consolidate all the Ipca Group's USA generic formulations business under one entity. a) Sale of all rights, title and interest in the product approvals and all goodwill associated with nine (9) ANDAs owned by Bayshore for US Dollar Two Million Six Hundred Fifty Thousand ($2,650,000) through asset sale agreement subject to necessary consents/approvals to Unichem India; and b) Sale of all generic formulations marketing / distribution business of Bayshore in the US market as a going concern through slump sale/transfer of entire business (debt free) and all goodwill associated with the business through business sale agreement for US Dollar Ten Millions ($10,000,000) to Unichem USA. (As per BSE Announcement dated on 30/09/2024)
24-Jul-2024	13-Aug-2024	Quarterly Results	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Standalone and Consolidated unaudited financial results of the Company for the 1st quarter ended 30th June 2024 of the financial year 2024-25 Standalone and Consolidated Unaudited Financial Results for Q1FY25 (As Per BSE Announcement Dated on 13.08.2024)
07-May-2024	29-May-2024	Final Dividend	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Standalone and Consolidated Audited Financial Results for the 4th quarter and financial year ended 31st March 2024 and recommendation of final dividend for FY 23-24 Board recommends final dividend Outcome of Board Meeting held on 29th May, 2024 (As Per BSE Announcement dated on 29.05.2024)
22-Jan-2024	14-Feb-2024	Quarterly Results	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the 3rd quarter and nine months ended 31.12.2023 Outcome of Board Meeting held on 14.02.2024 Standalone and Consolidated Q3FY24 Results and Press Release (As Per BSE Announcement Dated on 14/02/2024)
25-Oct-2023	10-Nov-2023	Quarterly Results	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve Standalone and Consolidated Unaudited Results for Q2 H1FY24 and Interim Dividend Record Date for Interim Dividend 2023-24 Board approves Dividend Board has approved Interim dividend of Rs. 2/- per equity share (200%) Standalone and Consolidated Results for 2nd quarter and half year ended 30th September, 2023 (As Per BSE Announcement Dated on 10.11.2023)
21-Jul-2023	10-Aug-2023	Quarterly Results	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for 1st quarter ended 30th June 2023. Standalone and Consolidated Q1FY24 Results & Press Release (As Per BSE Announcement dated on 10.08.2023)
12-May-2023	29-May-2023	Accounts	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve Audited Financial Results for the 4th quarter and financial year ended 31st March 2023 We are enclosing herewith Audited Financial Results, Standalone and Consolidated for the 4th quarter and financial year ended 31st March, 2023 which were taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai. (As Per BSE Announcement dated on 29.05.2023)
24-Apr-2023	24-Apr-2023	Acquisitions	Outcome of the Board Meeting - Acquisition of 33.38% of the paid-up equity share capital of Unichem Laboratories Ltd. (506690 on BSE: UNICHEMLAB on NSE)
20-Jan-2023	14-Feb-2023	Quarterly Results	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the 3rd quarter and nine months ended 31st December 2022. Standalone and Consolidated Unaudited Financial Results along with limited review reports of the Company's Statutory Auditors thereon for the 3rd Quarter and nine months ended 31st December, 2022, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai. Re-designation of Whole-time Directors (As per BSE Announcement Dated on 14/02/2023)
02-Nov-2022	11-Nov-2022	Quarterly Results	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the 2nd quarter and half year ended 30th September 2022; and to consider declaration of Interim Dividend for the financial year 2022-23. Record Date for Interim Dividend for Financial year 2022-23 Standalone and Consolidated Q2FY23 Results & Press Release / Interim Dividend Board approves Dividend of Rs. 4/- (400%) per share. (As Per BSE Announcement Dated 11.11.2022)
20-Oct-2022	20-Oct-2022	Change in Directors	Appointment of Dr. Narendra Mairpady (DIN 00536905) as a Director / Independent Director
28-Jul-2022	10-Aug-2022	Quarterly Results	IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 inter alia to consider and approve Unaudited financial results of the Company for the 1st quarter ended 30th June 2022 of the financial year 2022-23. Standalone and Consolidated Unaudited Financial Results for the 1st Quarter ended 30th June, 2022 of the financial year 2022-23 (As Per BSE Announcement dated on 10.08.2022)

1 2

LOGIN HERE

Ipca Laboratories Ltd

Board Meeting